Targeted Nanoparticles Degrading Tumor Stroma for Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments face challenges in delivering therapeutic agents effectively due to the dense tumor stroma, abnormal vasculature, high interstitial pressure, and extensive fibrosis in tumors, which impede drug penetration and distribution.
Innovation Solution
The development of nanoparticles conjugated with a recombinant fusion polypeptide comprising a urokinase plasminogen activator (uPA) sequence and a matrix metalloprotease (MMP) catalytic domain, which targets urokinase plasminogen activator receptor (uPAR) and degrades extracellular matrix proteins, facilitating drug delivery into tumor cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chemotherapy agents are administered systemically, then cancer treatment is provided, but drug delivery is impeded by dense tumor stroma and abnormal vasculature
Solution Approach 1:
The nanoparticle is pre-conjugated with a recombinant fusion polypeptide that has both uPA binding capability and MMP catalytic activity. Upon reaching the tumor site, the polypeptide first binds to uPAR on tumor cells and stromal cells, then the MMP domain degrades extracellular matrix proteins in advance, creating a pathway for drug delivery before the actual therapy is administered.
Solution Approach 2:
The recombinant fusion polypeptide acts as an intermediary molecule that performs dual functions: it binds to uPAR receptors on tumor cells and stromal cells to anchor the nanoparticle, while simultaneously activating MMP enzymes to degrade extracellular matrix proteins. This intermediary action removes the stromal barrier and facilitates subsequent drug delivery into tumor cells.
2Reliability
If therapeutic agents are delivered to tumor tissues, then cancer treatment efficacy is improved, but systemic toxicity increases
Solution Approach 1:
The nanoparticle is designed with a targeting mechanism that concentrates the therapeutic agent specifically at the tumor site. The uPA-uPAR binding interaction provides selective accumulation in tumor tissues where uPAR is overexpressed, while normal tissues with low uPAR expression remain unaffected. This local concentration effect improves treatment efficacy while minimizing systemic toxicity.
3Quantity of substance
If nanoparticles are used for targeted delivery, then bioavailability to tumor tissues is increased, but manufacturing complexity increases
Solution Approach 1:
The recombinant fusion polypeptide merges two functional domains into a single molecule: the uPA binding domain for receptor recognition and the MMP catalytic domain for matrix degradation. This consolidation of multiple functions into one conjugated unit simplifies the nanoparticle design compared to using separate targeting molecules and enzymatic agents, while still achieving high bioavailability through targeted delivery.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enhances the intratumoral delivery and distribution of nanoparticles, overcoming the stromal barrier and improving the efficacy of cancer therapy by increasing the accumulation of therapeutic agents within tumor tissues.
Implementation Method 1
a targeting molecule is linked to the nanoparticle... the targeting molecule binds a molecule more highly expressed on cancer cells then non-cancerous cells
Implementation Method 2
a catalytic domain of a protease is linked to the nanoparticle... degrades extracellular matrix proteins
Data Source
AI summary
This disclosure relates to targeted protease compositions and uses related thereto. In certain embodiments, the disclosure relates to nanoparticles wherein a targeting molecule is linked to the nanoparticle and wherein a catalytic domain of a protease is linked to the nanoparticle. In certain embodiments, the targeting molecule and the catalytic domain are within a single polypeptide sequence. In certain embodiments, the targeting molecule binds a molecule more highly expressed on cancer cells then non-cancerous cells, and the nanoparticles disclosed herein are used for the treatment of cancer by further attaching an anti-cancer agent to the nanoparticle or incorporating an anticancer agent within the nanoparticle.